Protagonist Therapeutics saw the highest growth of 2.49% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.17% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Protagonist Therapeutics’s patent filings and grants. Buy the databook here.
Protagonist Therapeutics has been focused on protecting inventions in United States(US) with seven publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 50% filings and 100% grants. The United States(US), European Patent Office(EPO), and Japan(JP) patent Office are among the top ten patent offices where Protagonist Therapeutics is filings its patents. Among the top granted patent authorities, Protagonist Therapeutics has 100% of its grants in United States(US).
Immatics could be the strongest competitor for Protagonist Therapeutics
Patents related to rare diseases lead Protagonist Therapeutics's portfolio
Protagonist Therapeutics has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
Ileitis related patents lead Protagonist Therapeutics portfolio followed by inflammatory bowel disease, and hemochromatosis
Protagonist Therapeutics has highest number of patents in ileitis followed by inflammatory bowel disease, hemochromatosis, ulcerative colitis, and sinusitis. For ileitis, nearly 6% of patents were filed and 4% of patents were granted in Q2 2024.
For comprehensive analysis of Protagonist Therapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.